The Pentagon Just Picked a $10 Stock to Power Its Drones. The Real Story Is Who’s Actually Building Those Cells.

(SeaPRwire) –   By: Ethan Gallagher

Let me be blunt about what just happened. Amprius Technologies popped 10% in premarket Monday because the U.S. Department of War handed it up to $75 million. The press release frames this as a victory for American battery innovation. Silicon anodes. High energy density. Drones. All very clean, very tidy. But I’ve spent the last fifteen years walking fab floors and reading retrofit specs, and I can tell you what this actually is. It is not a technology breakthrough. It is a capacity conversion. An existing EV battery line, currently run by a major South Korean manufacturer, gets retooled to spit out military-grade cells by early 2028. The government is paying $75 million of a roughly $100 million project. That is not R&D funding. That is procurement pre-positioning dressed up in a lab coat. The interesting question was never whether silicon anodes beat graphite on a weight basis. Everyone knows that. The question is whether a $34 million quarterly revenue company can actually hit 12 million cells a year without the quality control slipping. And whether “domestic, NDAA-compliant production” is a real moat or just a line item in a solicitation document.

Here is what the official release actually says, stripped of the adjectives. The grant flows through the Industrial Base Analysis and Sustainment program, which is the DoW’s vehicle for funding domestic manufacturing tied to national security. The facility will produce high-energy-density cells for Group 1, 2, and 3 unmanned aerial systems. That is the small-to-mid-size drone tier. Not the long-endurance HAPS platforms. Not the heavy strike airframes. The target completion window is early 2028. Annual capacity at full ramp: roughly 12 million cells. The full project costs about $100 million. Amprius and its South Korean partner cover the gap beyond the $75 million grant through in-kind contributions. The legal instrument behind all of this is called Project acCELLerate. It is fixed-price and milestone-based. Approximately $22 million was already obligated from FY2025 funds. The agreement runs from September 2026 through September 2028. Amprius’s CEO Tom Stepien called it a way to establish “a primary source of domestic, NDAA-compliant battery production.” The company’s fiscal 2026 revenue guide sits above $140 million against a $132.10 million Street estimate. Q2 revenue came in at $34.03 million, beating the $29.30 million consensus. Adjusted loss per share for the quarter was 2 cents, in line with expectations. Full-year GAAP loss guidance: 8 cents, a penny worse than the 7-cent analyst estimate.

Now the subtext. The stock traded near $10.70 after the news. The Buy consensus price target across coverage is $31.50. Jones Trading initiated at $30 in July. Clear Street came in at $33 in June. Needham has held a $20 target since March and has not budged. That spread alone tells you the sell-side is pricing in a lot of optimism that the grant does not actually guarantee. The 12 million cells per year sounds big until you do the math against a Group 3 drone fleet that might field hundreds of airframes, each consuming several hundred cells over its service life. The “South Korean manufacturing know-how” pairing is the part the release buries. Amprius designs the silicon anode architecture. The partner operates the line. That is not a neutral footnote. That is a geopolitical dependency baked into a national security supply chain. The NDAA sourcing rules are the actual competitive weapon here, not the chemistry. Any company that can produce domestically compliant cells gets locked into the defense procurement pipeline. Foreign-made batteries simply cannot clear those doors. Amprius is not winning on electrochemistry. It is winning on paperwork. And the $22 million already pulled from FY2025 funds signals that this program was being quietly shaped before the public announcement hit the wire.

The supply chain landscape for drone batteries in the Western world is going to consolidate around whoever controls the domestic cell lines by 2028. Not the OEMs. Not the drone makers. The cell suppliers. The fixed-price, milestone-based structure of Project acCELLerate means the DoW bears the schedule risk, not Amprius. If that line misses its early 2028 target, the government absorbs the penalty. That asymmetry is why a company with a 2-cent quarterly adjusted loss can command a $31.50 average target while trading at $10.70. The market is not pricing the battery. It is pricing the procurement lock-in. One domestic, NDAA-compliant cell source for Groups 1 through 3 is a bottleneck that the next Pentagon acquisition strategy will be forced to route through. Whoever owns that bottleneck in 2028 owns a toll booth on every medium-altitude unmanned mission the U.S. fields thereafter. The grant is not a bet on Amprius. It is a bet on having exactly one domestic gate, and no one else, by the time the next acquisition cycle opens.

Author bio: Ethan Gallagher, a Silicon Valley Hardware Architect and Infrastructure Strategist with two decades in battery and semiconductor fab design, specializing in defense-adjacent manufacturing supply chains and domestic capacity conversion projects.